11 April 2022
The team, headed by Manuel Valiente from CNIO, which counts with the contributions of scientists from other Research Centres, namely the Champalimaud Foundation, found that a simple blood test can help detect patients with resistance to brain radiotherapy and identified a drug that might reverse it. A multi-centre clinical study is now under way to validate the predictive potential of this biomarker through the National Brain Metastasis Network (Spanish acronym: RENACER).
The study is being published in Nature Medicine this week.
07 April 2022
For rectal cancer, our goal is to use the “avatar fish” test to help identify which patients should not be submitted to radiotherapy because their tumour does not respond to radiation
Rita Fior uses zebrafish to do basic and translational research in cancer at the Champalimaud Foundation. A few years ago, having to deal with cancer in her family led her to design a test, based on her animal “model” – that would allow doctors to choose, among the available chemotherapeutic options, the best one for a given patient. How? Using the little zebrafish as “avatars”, as personalised “alter-egos” of the patients. Tumour cells from a patient are injected in the fish, generating the “avatars'' that will then be submitted to the treatment options available for that patient.
Florence Nightingale na Era Digital: “Onde estamos e para onde vamos?"
A Fundação Champalimaud, enquanto instituição prestadora de cuidados na área da oncologia e centro privilegiado de aprendizagem, promove anualmente uma conferência multidisciplinar onde aborda transversalmente o que de mais inovador e diferenciador se faz em oncologia.
20 March 2022
In 2015, the Champalimaud Foundation established the International Training Academy in Robotic Colorectal Surgery
Interview with Amjad Parvaiz
As a young man, Amjad Parvaiz, now 54, wanted to become a “big trauma surgeon”. So after graduating from university in his home city of Lahore, in Pakistan, he moved to South Africa to do his trauma surgery training there. While in South Africa, in 1995, he says, “one of my bosses took me aside and said to me: ‘if you want to do 21st century surgery, go and learn laparoscopy.
09 March 2022
In just ten years, colorectal cancer cases have doubled in people under 50
Interview with Paulo Fidalgo
Paulo Fidalgo, 66, says that he has “two loves” at the Champalimaud Foundation: gastroenterology and oncological risk assessment. So it does not come as a surprise that he is both a gastroenterologist in the Digestive Unit of the Champalimaud Clinical Centre and the head of the Risk Assessment and Early Diagnosis Programme at this Centre.
